explore -WSS

explore

author：explore 2025-09-02 22:25:47 - browse：678

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

LONDON — Regulators in the U.K. on Thursday approved a CRISPR-based medicine to treat both sickle cell disease and beta thalassemia, making it the world’s first therapy built on the revolutionary gene-editing technology and ushering in a new era of genetic medicine.

The authorization of the therapy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is itself not a surprise. Clinical trials have shown the one-time treatment enabled many sickle cell patients to live free of debilitating pain crises and relieved thalassemia patients of needing regular blood transfusions, raising hopes that they have been effectively cured. But it also stands as a major achievement, coming just over a decade after the first and seminal lab experiments that showed CRISPR’s potential as a gene-editing tool were published.

In granting conditional approval to the therapy, which will have the brand name Casgevy and is also known as exa-cel, the U.K.’s Medicines and Healthcare products Regulatory Agency jumped ahead of its counterparts in the U.S. and Europe, which are also reviewing the medicine, in greenlighting the globe’s first CRISPR treatment. The MHRA’s authorization is for patients who are at least 12 years old.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Surge of respiratory disease in China has likely explanation

focus

WSS

STAT Virtual Event: ASCO Recap, Live!

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

'Essentially witchcraft:' A former naturopath takes on the field

New report analyzes digital physical therapy solutions' effectiveness

New report analyzes digital physical therapy solutions' effectiveness

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

knowledge

explore

hotspot

At least 13 dead in Texas as scorching temps continue

Statins may not be needed by millions of people, study suggests

Continuity nursing helped my family in our darkest PICU moments

Moderna says combo Covid

Cancer drug shortages should be causing more outrage

Statins may not be needed by millions of people, study suggests

ChatGPT in medicine: STAT answers readers' burning questions

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Continuity nursing helped my family in our darkest PICU moments

Childhood cancer progress stalls for Black, Hispanic kids: Report

hotspot

Medical device trials still don't enroll enough women, study finds

Morphosys mixed study results for blood cancer drug

Medical device trials still don't enroll enough women, study finds

Curing rare childhood diseases will falter unless Congress steps up

Ransomware attacks on hospitals: Study outlines patient impact

Childhood cancer progress stalls for Black, Hispanic kids: Report

hotspot

focus

Wikipedia

focus